Hydroxychloroquine shows no coronavirus benefit, raises death risk – study

Latest News

Hydroxychloroquine shows no coronavirus benefit, raises death risk – study

Friday, May 22, 2020

Print this page Email A Friend!


PARIS, France (AFP)— A study of nearly 100,000 coronavirus patients has shown no benefit in treating them with anti-viral drugs hydroxychloroquine and chloroquine and even increased the likelihood of them dying in hospital.

Hydroxychloroquine is normally used to treat arthritis but pronouncement from public figures including US President Donald Trump -- who announced this week he is taking the drug -- has prompted governments to bulk buy the medicine.

Chloroquine is an anti-malarial. Both drugs can produce potentially serious side effects, particularly heart arrhythmia.

Authors of a study published Friday in The Lancet said they found that the two medicines had no effect on the outcome of patients hospitalised with COVID-19.

Looking at the records of 96,000 patients across hundreds of hospitals, they found that administering the drugs actually increased the risk of dying.

They compared outcomes from four groups: those treated with hydroxychloroquine alone, with chloroquine alone, and then two groups given the respective drugs in combination with antibiotics.

There was also a control group of patients not given these treatments.

At the end of the study period around nine per cent of those in the control group had died.

Of those treated with hydroxychloroquine or chloroquine alone, 18 per cent and 16.4 per cent respectively had died.

And those given each drug in combination with antibiotics were even more likely to die: 22.8 per cent with chloroquine and 23.8 per cent with hydroxychloroquine.

The authors estimated that the drugs put patients at up to 45 per cent higher risk of dying from COVID-19 compared with underlying health issues.

"Treatment with chloroquine or hydroxychloroquine does not benefit patients with COVID-19," said Mandeep Mehra, lead author of the study and executive director of the Brigham and Women's Hospital Center for Advanced Heart Disease in Boston.

"Instead, our findings suggest it may be associated with an increased risk of serious heart problems and increased risk of death."

Despite Trump's enthusiasm for using hydroxychloroquine for COVID-19 treatment, his own government's Food and Drug Administration warns against it.

Brazil's health minister on Wednesday recommended using chloroquine and hydroxychloroquine to treat even mild COVID-19 cases.

Britain has ordered 35 million (US$42 million, 40 million euros) worth of hydroxychloroquine, despite numerous studies showing it is ineffective in treating COVID-19 and may even be more dangerous than doing nothing.

"Several countries have advocated use of chloroquine and hydroxychloroquine, either alone or in combination, as potential treatments for COVID-19," said Frank Ruschitzka, director of the Heart Centre at University Hospital Zurich and co-author of the study.

"We now know from our study that the chance that these medications improve outcomes in COVID-19 is quite low."


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaperlive


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT